StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Oxymorphon

Oxymorphone

HCID 5284604
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
76-41-5
Standard-SMILES
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
InChIKey
UQCNKQCJZOAFTQ-ISWURRPUSA-N
Summenformel
C17H19NO4
Durchschnittliche Molmasse
301,34 g/mol
Monoisotopische Masse
301,13140809

Überblick

Oxymorphone is a morphinane alkaloid.

Namen und Bezeichner

Bevorzugter Name
Oxymorphone
IUPAC
(4R,4aS,7aR,12bS)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
Lokaler Name
Oxymorphon
Englischer Name
OXYMORPHONE
Summenformel
C17H19NO4
Molmasse
301.34

Namen und Synonyme

oxymorphone76-41-5Oximorphonum14-HydroxydihydromorphinoneDihydrohydroxymorphinoneDihydroxymorphinoneOximorfona(-)-Oxymorphone7,8-Dihydro-14-hydroxymorphinoneOxymorphonumOxymorphone ciiDihydro-14-hydroxymorphinone
Weitere Namen anzeigen
NSC 19045NumorphanOxymorphineOxymorphone (CRM)Naltrexone Impurity 15OXYMORPHONE (MW 301.35)
(14S)-14-HydroxydihydromorphinoneMorphinone, dihydro-14-hydroxy-NSC-190459VXA968E0CIDS-NO-003NIH 10323DTXSID5023409NSC19045

Datenbank-Bezeichner

CAS
76-41-5
PubChem CID
5284604
DTXSID
DTXSID5023409
ChEMBL
CHEMBL963
ChEBI
CHEBI:7865
UNII

Eigenschaften

Berechnete Struktureigenschaften

XLogP
0,8
Polarare Oberfläche (TPSA)
70 Ų
H-Brücken-Donoren
2
H-Brücken-Akzeptoren
5
Frei drehbare Bindungen
0
Schwere Atome
22
Formalladung
0
Komplexität
539

Experimentelle und physikochemische Eigenschaften

Drugs · 5 Einträge

DEA NFLIS-Drug Category -> Narcotic Analgesics

DEA Schedule II Controlled Substance

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Synthetic Cannabinoids or Psychoactive Compounds

Pharmaceuticals -> Metabolite of Oxycodone

LogP · 2 Einträge

log Kow = 0.83

0.67

Color/FormCrystals from boiling ethanol, ethyl acetate, or benzene
Solubility · 2 Einträge

Soluble in boiling acetone and chloroform; readily soluble in aqueous alkalies; moderately soluble in boiling ethanol; sparingly soluble in benzene

2.56e+01 g/L

Human Drugs · 2 Einträge

Breast Feeding; Lactation; Milk, Human; Analgesics, Opioid; Narcotics

Pharmaceuticals

Endocrine DisruptorsPotential endocrine disrupting compound
Melting Point · 3 Einträge

248-249 °C

248-249 °C (decomposes)

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 5 Einträge

This chemical does not meet GHS hazard criteria for 2% (1 of 49) of reports.

Danger

H300 (87.8%): Fatal if swallowed [Danger Acute toxicity, oral]

P260, P262, P264, P270, P271, P280, P284, P301+P316, P302+P352, P304+P340, P316, P320, P321, P330, P361+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 49 reports by companies from 8 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Regulatory Information · 2 Einträge

DEA schedule II controlled substance

REACH registered substance: Oxymorphone (EC: 200-959-7)

FDA Requirements · 4 Einträge

Oxymorphone hydrochloride injection. ... The drug is a narcotic analgesic, preanesthetic, anesthetic, and substitute anesthetic adjuvant for intramuscular, subcutaneous or intravenous administration to cats and dogs.

Schedule II shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Each drug or substance has been assigned the DEA Controlled Substances Code Number set forth opposite it. Unless specifically excepted or unless listed in another schedule, any of the following substances whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis: (1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate excluding apomorphine, thebaine-derived butorphanol, dextrorphan, nalbuphine, nalmefene, naloxone, and naltrexone, and their respective salts, but including the following. Oxymorphone (DEA Code Number: 9652) is included on this list.

The Approved Drug Products with Therapeutic Equivalence Evaluations identifies currently marketed prescription drug products, including oxymorphone hydrochloride, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act. /Oxymorphone hydrochloroide/

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 2 Einträge

N - Nervous system

QN - Nervous system

Pharmacodynamics · 1 Eintrag

Oxymorphone is a semi-synthetic opioid substitute for morphine. It is a potent analgesic. Opioid analgesics exert their principal pharmacologic effects on the CNS and the gastrointestinal tract. The principal actions of therapeutic value are analgesia and sedation. Opioids produce respiratory depression by direct action on brain stem respiratory centers. The mechanism of respiratory depression involves a reduction in the responsiveness of the brain stem respiratory centers to increases in carbon dioxide tension and to electrical stimulation.

Mechanism of Action · 6 Einträge

Oxymorphone interacts predominantly with the opioid mu-receptor. These mu-binding sites are discretely distributed in the human brain, with high densities in the posterior amygdala, hypothalamus, thalamus, nucleus caudatus, putamen, and certain cortical areas. They are also found on the terminal axons of primary afferents within laminae I and II (substantia gelatinosa) of the spinal cord and in the spinal nucleus of the trigeminal nerve. Also, it has been shown that oxymorphone binds to and inhibits GABA inhibitory interneurons via mu-receptors. These interneurons normally inhibit the descending pain inhibition pathway. So, without the inhibitory signals, pain modulation can proceed downstream.

Oxymorphone is an opioid agonist whose principal therapeutic action is analgesia. ... In addition to analgesia, other pharmacological effects of opioid agonists include anxiolysis, euphoria, feelings of relaxation, respiratory depression, constipation, miosis, and cough suppression. Like all pure opioid agonist analgesics, with increasing doses there is increasing analgesia, unlike with mixed agonist/antagonists or non-opioid analgesics, where there is a limit to the analgesic effect with increasing doses. With pure opioid agonist analgesics, there is no defined maximum dose; the ceiling to analgesic effectiveness is imposed only by side effects, the more serious of which may include somnolence and respiratory depression.

The precise mechanism of the analgesic action is unknown. However, specific CNS (central nervous system) opioid receptors for endogenous compounds with opioid-like activity have been identified throughout the brain and spinal cord and play a role in the analgesic effects of this drug. In addition, opioid receptors have been identified within the PNS (peripheral nervous system). The role that these receptors play in these drugs' analgesic effects is unknown.

Zugehörige Reaktionen

30
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 478017
HRID 478017als Edukt
Reaktionsgleichung von HRID 478018
HRID 478018als Edukt
Reaktionsgleichung von HRID 515575
HRID 515575als Produkt
Reaktionsgleichung von HRID 515576
HRID 515576als Edukt
Reaktionsgleichung von HRID 845821
HRID 845821als Edukt
Reaktionsgleichung von HRID 845822
HRID 845822als Edukt
Reaktionsgleichung von HRID 1037632
HRID 1037632als Produkt
Reaktionsgleichung von HRID 1037633
HRID 1037633als Edukt
ZurückSeite 1 von 4

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
9VXA968E0C
EC Number
200-959-7
Nikkaji
J4.174B

248 - 249 °C

Physical DescriptionSolid
Dissociation Constants · 3 Einträge

8.17

pKa = 8.17

White to slightly off-white, odorless powder; sparingly soluble in alcohol and ether; freely soluble in water. MW 337.80. pKa1 = 8.17, pKa2 = 0.54 (37 °C). log Kow = 0.98, pH 7.4, 37 °C /Oxymorphone hydrochloride/

Collision Cross Section164.6 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]
Other Experimental PropertiesCrystals /Oxymorphine hydrochloride/

Physikochemische Eigenschaften

Schmelzpunkt
248 · 248-249°C (dec)
Siedepunkt
518.6 · 518.6±50.0 °C(Predicted)
Dichte
1.5 · 1.50±0.1 g/cm3(Predicted)
Flammpunkt
9 ℃ · 9℃
storage temp.
-20 °C · Controlled Substance, -20°C Freezer
Löslichkeit
Soluble in DMSO
Aggregatzustand
Powder
pka
8.5 · pKa 8.50 (Uncertain);9.33 (Uncertain)
Henry's Law Constant
2.4 · 2.4×1013 mol/(m3Pa) at 25℃, HSDB (2015)
InChI
1S/C17H19NO4/c1-18-7-6-16-13-9-2-3-10(19)14(13)22-15(16)11(20)4-5-17(16,21)12(18)8-9/h2-3,12,15,19,21H,4-8H2,1H3/t12-,15+,16+,17-/m1/s1
InChIKey
UQCNKQCJZOAFTQ-ISWURRPUSA-N
SMILES
CN1CC[C@]23[C@H]4Oc5c(O)ccc(C[C@@H]1[C@]2(O)CCC4=O)c35
EPA chemische Informationen
-6 · Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-methyl-, (5.alpha.)- (76-41-5)

The Generic Animal Drug and Patent Restoration act requires that each sponsor of an approved animal drug must submit to the FDA certain information regarding patents held for the animal drug or its method of use. The Act requires that this information, as well as a list of all animal drug products approved for safety and effectiveness, be made available to the public. Oxymorphone hydrochloride is included on this list. /Oxymorphone hydrochloride/

Hazard Classes and CategoriesAcute Tox. 2 (87.8%)

Sicherheit und Schutzausrüstung

Fire Fighting Procedures · 2 Einträge

As with all fires, evacuate personnel to a safe area. Firefighters should use self-contained breathing equipment and protective clothing.

Water spray, dry chemical, carbon dioxide, or foam as appropriate for surrounding fire and materials.

Storage Conditions · 2 Einträge

Store in tight container as defined in the USP-NF. This material should be handled and stored per label instructions to ensure product integrity.

Store at 25 °C (77 °F); excursions permitted to 15-30 °C (59-86 °F).

Cleanup Methods · 1 Eintrag

Wear approved respiratory protection, chemically compatible gloves, and protective clothing. Wipe up spillage or collect spillage using a high-efficiency vacuum cleaner. Avoid breathing dust. Place spillage in appropriately labeled container for disposal. Wash spill site.

Disposal Methods · 2 Einträge

SRP: Expired or waste pharmaceuticals shall carefully take into consideration applicable DEA, EPA, and FDA regulations. It is not appropriate to dispose by flushing the pharmaceutical down the toilet or discarding to trash. If possible return the pharmaceutical to the manufacturer for proper disposal being careful to properly label and securely package the material. Alternatively, the waste pharmaceutical shall be labeled, securely packaged and transported by a state licensed medical waste contractor to dispose by burial in a licensed hazardous or toxic waste landfill or incinerator.

SRP: Wastewater from contaminant suppression, cleaning of protective clothing/equipment, or contaminated sites should be contained and evaluated for subject chemical or decomposition product concentrations. Concentrations shall be lower than applicable environmental discharge or disposal criteria. Alternatively, pretreatment and/or discharge to a permitted wastewater treatment facility is acceptable only after review by the governing authority and assurance that "pass through" violations will not occur. Due consideration shall be given to remediation worker exposure (inhalation, dermal and ingestion) as well as fate during treatment, transfer and disposal. If it is not practicable to manage the chemical in this fashion, it must be evaluated in accordance with EPA 40 CFR Part 261, specifically Subpart B, in order to determine the appropriate local, state and federal requirements for disposal.

Preventive Measures · 4 Einträge

As a general rule, when handling USP Reference Standards, avoid all contact and inhalation of dust, mists, and/or vapors associated with the material. Wash thoroughly after handling.

As with all dry powders, it is advisable to ground mechanical equipment in contact with dry material to dissipate the potential buildup of static electricity.

SRP: Contaminated protective clothing should be segregated in such a manner so that there is no direct personal contact by personnel who handle, dispose, or clean the clothing. The completeness of the cleaning procedures should be considered before the decontaminated protective clothing is returned for reuse by the workers. Contaminated clothing should not be taken home at the end of shift, but should remain at employee's place of work for cleaning.

SRP: Local exhaust ventilation should be applied wherever there is an incidence of point source emissions or dispersion of regulated contaminants in the work area. Ventilation control of the contaminant as close to its point of generation is both the most economical and safest method to minimize personnel exposure to airborne contaminants. Ensure that the local ventilation moves the contaminant away from the worker.

Personal Protective Equipment (PPE) · 2 Einträge

Respiratory Protection: Where respirators are deemed necessary to reduce or control occupational exposures, use NIOSH-approved respiratory protection and have an effective respirator program in place. Gloves: Chemically compatible. For handling solutions, ensure that the glove material is protective against the solvent being used. Use handling practices that minimize direct hand contact. Employees who are sensitive to natural rubber (latex) should use nitrile or other synthetic nonlatex gloves. Use of powdered latex gloves should be avoided due to the risk of latex allergy. Eye Protection: Safety glasses with sideshields are recommended. Face shields or goggles may be required if splash potential exists or if corrosive materials are present. Approved eye protection (e.g., bearing the ANSI Z87 or CSA stamp) is preferred. Maintain eyewash facilities in the work area. Protective clothing: For handling of laboratory scale quantities, a cloth lab coat is recommended. Where significant quantities are handled, work clothing may be necessary to prevent take-home contamination.

Airborne exposure should be controlled primarily by engineering controls such as general dilution ventilation, local exhaust ventilation, or process enclosure. Local exhaust ventilation is generally preferred to general exhaust because it can control the contaminant at its source, preventing dispersion into the work area. An industrial hygiene survey involving air monitoring may be used to determine the effectiveness of engineering controls. Effectiveness of engineering controls intended for use with highly potent materials should be assessed by use of nontoxic surrogate materials. Avoid any open handling of this material, particularly for grinding, crushing, weighing, or other dust-generating or aerosol-generating procedures. Use a laboratory fume hood, vented enclosure, glovebox, or other effective containment.

Toxikologische Informationen

Body Burden · 3 Einträge

... Blood concentrations were 0.05 mg/L (50 ug/L) and 0.12 mg/L (120 ug/L). /fatal/

The mean concentration for oxymorphone in postmortem central (n = 28) and peripheral (n = 23) blood samples was 0.15 mg/L. The median values for the central and peripheral samples were 0.10 mg/L (range: 0.011-0.59) and 0.075 mg/L (range: 0.017-0.82), respectively. Liver concentrations ranged from "none detected" to > 2.0 mg/kg, with mean and median values of 0.36 and 0.30 mg/kg, respectively. The majority of urine samples were > 0.50 mg/L. /fatal/

Toxicology on the deceased female revealed the presence of 0.13 mg/L oxymorphone ... in her blood. Gastric contents contained 0.25 mg/L of oxymorphone ... /fatal/

Treatment · 1 Eintrag

Primary attention should be given to the reestablishment of adequate respiratory exchange through provision of a patent airway and the institution of assisted or controlled ventilation. The opioid antagonist naloxone hydrochloride is a specific antidote against respiratory depression which may result from overdosage or unusual sensitivity to opioids including oxymorphone. Therefore, an appropriate dose of naloxone hydrochloride should be administered (usual initial adult dose 0.4 mg-2 mg) preferably by the intravenous route and simultaneously with efforts at respiratory resuscitation. Since the duration of action of oxymorphone may exceed that of the antagonist, the patient should be kept under continued surveillance and repeated doses of the antagonist should be administered as needed to maintain adequate respiration. Naloxone hydrochloride should not be administered in the absence of clinically significant respiratory or cardiovascular depression. In addition, it should be considered that the use of an opioid antagonist in patients physically dependent on opioids may precipitate an acute withdrawal syndrome that cannot be readily suppressed while the action of the antagonist persists. If respiratory depression is associated with muscular rigidity, administration of a neuromuscular blocking agent may be necessary to facilitate assisted or controlled ventilation. Muscular rigidity may also respond to opioid antagonist therapy. Oxygen, intravenous fluids, vasopressors and other supportive measures should be employed as indicated. (L1712)

Interactions · 5 Einträge

Oxymorphone may be expected to have additive effects when used in conjunction with alcohol, other opioids, or illicit drugs that cause central nervous system depression because respiratory depression, hypotension, and profound sedation or coma may result.

Patients receiving other opioid analgesics, general anesthetics, phenothiazines, other tranquilizers, sedatives, hypnotics, or other CNS depressants (including alcohol) concomitantly with oxymorphone may exhibit an additive CNS depression. Interactive effects resulting in respiratory depression, hypotension, profound sedation, or coma may result if these drugs are taken in combination with the usual dose of oxymorphone injection.

Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, and buprenorphine) should be administered with caution to a patient who has received or is receiving a course of therapy with a pure opioid agonist analgesic such as oxymorphone. In this situation, mixed agonist/antagonist analgesics may reduce the analgesic effect of oxymorphone and/or may precipitate withdrawal symptoms in these patients.

No specific interaction between oxymorphone and monoamine oxidase inhibitors has been observed, but caution in the use of any opioid in patients taking this class of drugs is appropriate.

For more Interactions (Complete) data for Oxymorphone (11 total), please visit the HSDB record page.

Health EffectsMedical problems can include congested lungs, liver disease, tetanus, infection of the heart valves, skin abscesses, anemia and pneumonia. Death can occur from overdose.
Environmental Fate · 3 Einträge

TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 160(SRC), determined from a structure estimation method(2), indicates that oxymorphone is expected to have moderate mobility in soil(SRC). The pKa of oxymorphone is 8.17(3), indicating that this compound will exist partially in the cation form in the environment and cations generally adsorb more strongly to soils containing organic carbon and clay than their neutral counterparts(4). Volatilization of the neutral species from moist soil surfaces is not expected to be an important fate process(SRC) given an estimated Henry's Law constant of 4.1X10-19 atm-cu m/mole(SRC), using a fragment constant estimation method(5). Oxymorphone is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 4.6X10-11 mm Hg at 25 °C(SRC), determined from a fragment constant method(6). Biodegradation data in soil were not available(SRC, 2012).

AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 160(SRC), determined from a structure estimation method(2), indicates that oxymorphone is expected to adsorb to suspended solids and sediment(SRC). Volatilization of the neutral species from water surfaces is not expected(3) based upon an estimated Henry's Law constant of 4.1X10-19 atm-cu m/mole(SRC), developed using a fragment constant estimation method(4). A pKa of 8.17(5) indicates oxymorphone will exist partially in the cation form at pH values of 5 to 9, and therefore volatilization from water surfaces is not expected to be an important fate process(SRC). According to a classification scheme(6), an estimated BCF of 3(SRC), from its log Kow of 0.83(7) and a regression-derived equation(8), suggests the potential for bioconcentration in aquatic organisms is low(SRC). Biodegradation data in water were not available(SRC, 2012).

ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), oxymorphone, which has an estimated vapor pressure of 4.6X10-11 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), is expected to exist solely in the particulate phase in the ambient atmosphere. Particulate-phase oxymorphone may be removed from the air by wet or dry deposition(SRC). Oxymorphone does not contain chromophores that absorb at wavelengths >290 nm(4) and, therefore, is not expected to be susceptible to direct photolysis by sunlight(SRC).

Exposure RoutesEnteral(rectal).
Toxicity Summary · 1 Eintrag

Oxymorphone interacts predominantly with the opioid mu-receptor. These mu-binding sites are discretely distributed in the human brain, with high densities in the posterior amygdala, hypothalamus, thalamus, nucleus caudatus, putamen, and certain cortical areas. They are also found on the terminal axons of primary afferents within laminae I and II (substantia gelatinosa) of the spinal cord and in the spinal nucleus of the trigeminal nerve. Also, it has been shown that oxymorphone binds to and inhibits GABA inhibitory interneurons via mu-receptors. These interneurons normally inhibit the descending pain inhibition pathway. So, without the inhibitory signals, pain modulation can proceed downstream.

Signs and Symptoms · 1 Eintrag

Oxymorphone overdosage is characterized by respiratory depression, extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, and sometimes bradycardia and hypotension. In a severe case of overdose, apnea, circulatory collapse, cardiac arrest, and death may occur.

Soil Adsorption/Mobility · 1 Eintrag

Using a structure estimation method based on molecular connectivity indices(1), the Koc of oxymorphone can be estimated to be 160(SRC). According to a classification scheme(2), this estimated Koc value suggests that oxymorphone is expected to have moderate mobility in soil. The pKa of oxymorphone is 8.17(3), indicating that this compound will exist partially in the cation in the environment and cations generally adsorb more strongly to soils containing organic carbon and clay than their neutral counterparts(4).

Human Toxicity Excerpts · 5 Einträge

/SIGNS AND SYMPTOMS/ Acute overdosage with oxymorphone injection is characterized by respiratory depression, (a decrease in respiratory rate and/or tidal volume, Cheyne-Stokes respiration, cyanosis), extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils and sometimes bradycardia and hypotension. In severe overdosage, apnea, circulatory collapse, cardiac arrest and death may occur. Oxymorphone injection may cause miosis, even in total darkness. Pinpoint pupils are a sign of opioid overdose but are not pathognomonic (e.g., pontine lesions of hemorrhagic or ischemic origin may produce similar findings). Marked mydriasis rather than miosis may be seen with hypoxia in overdose situations.

/CASE REPORTS/ ... To date, there are very few reported values for postmortem concentrations of oxymorphone in the literature to aid in the interpretation of these cases. /Investigators/ report 33 medical examiner cases involving oxymorphone and provide the distribution of oxymorphone in postmortem blood, liver, and urine samples. Oxymorphone was detected in blood by enzyme immunoassay and confirmed by gas chromatography- mass spectrometry utilizing a solid-phase extraction procedure. Calibration curves from 0.025 to 0.50 mg/L were established with a limit of quantitation of 0.025 mg/L. The mean concentration for oxymorphone in postmortem central (n = 28) and peripheral (n = 23) blood samples was 0.15 mg/L. The median values for the central and peripheral samples were 0.10 mg/L (range: 0.011-0.59) and 0.075 mg/L (range: 0.017-0.82), respectively. Liver concentrations ranged from "none detected" to > 2.0 mg/kg, with mean and median values of 0.36 and 0.30 mg/kg, respectively. The majority of urine samples were > 0.50 mg/L.

/CASE REPORTS/ There has been an increased awareness of illicit opiate abusers using the narcotic oxymorphone (Opana) by inhalation. Many laboratory screening techniques currently in use cannot detect oxymorphone in blood or urine. Consequently, biological specimens containing low to moderate concentrations of oxymorphone will likely go undetected. The circumstances, pathology findings, and toxicology results of two fatalities involving oxymorphone are presented. An opiate confirmation gas chromatography-mass spectrometry (GC-MS) procedure, described in detail was able to detect, confirm, and quantify oxymorphone in both subjects. The blood concentrations were 0.05 mg/L (50 ug/L) and 0.12 mg/L (120 ug/L).

/CASE REPORTS/ Two cases are reported involving the abuse of extended-release oxymorphone hydrochloride tablets (Opana ER) in combination with alprazolam (Xanax). Two juvenile females were discovered unresponsive and hypoxic by a male acquaintance. The trio had reportedly crushed and snorted Opana ER tablets and consumed Xanax for recreational purposes. Emergency personnel were able to stabilize one female. The second female was pronounced dead at the scene. Blood and urine samples from the surviving female were collected at the trauma center between 48 and 96 hr post incident. Toxicology results showed the presence of oxymorphone, doxylamine, dextromethorphan, alprazolam, alpha-hydroxyalprazolam, oxazepam, and temazepam in her urine. No drugs were detected in her blood. Toxicology on the deceased female revealed the presence of 0.13 mg/L oxymorphone and 0.04 mg/L alprazolam in her blood. Gastric contents contained 0.25 and 0.93 mg/L of oxymorphone and alprazolam, respectively. Oxymorphone, alprazolam, and alpha-hydroxyalprazolam were present in her urine. Quantitative results were achieved by gas chromatography-mass spectrometry monitoring selected ions for the oxime-oxymorphone-trimethylsilyl derivative, alprazolam, and the alpha-hydroxyalprazolam tert-butyldimethylsilyl derivative. The established linearity ranges for the opiate and benzodiazepine methods were 0.050-3.000 and 0.025-1.000 mg/L, respectively. The cause of death was reported as multiple drug toxicity, and the manner of death was accidental.

Artificial Pollution SourcesOxymorphone's production and administration as an analgesic(1) and substance of abuse(2) may result in its release to the environment through various waste streams(SRC).
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).

Regulatorische Informationen

FDA Requirements · 4 Einträge

Oxymorphone hydrochloride injection. ... The drug is a narcotic analgesic, preanesthetic, anesthetic, and substitute anesthetic adjuvant for intramuscular, subcutaneous or intravenous administration to cats and dogs.

Schedule II shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Each drug or substance has been assigned the DEA Controlled Substances Code Number set forth opposite it. Unless specifically excepted or unless listed in another schedule, any of the following substances whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis: (1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate excluding apomorphine, thebaine-derived butorphanol, dextrorphan, nalbuphine, nalmefene, naloxone, and naltrexone, and their respective salts, but including the following. Oxymorphone (DEA Code Number: 9652) is included on this list.

The Approved Drug Products with Therapeutic Equivalence Evaluations identifies currently marketed prescription drug products, including oxymorphone hydrochloride, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act. /Oxymorphone hydrochloroide/

The Generic Animal Drug and Patent Restoration act requires that each sponsor of an approved animal drug must submit to the FDA certain information regarding patents held for the animal drug or its method of use. The Act requires that this information, as well as a list of all animal drug products approved for safety and effectiveness, be made available to the public. Oxymorphone hydrochloride is included on this list. /Oxymorphone hydrochloride/

Sicherheitsdaten

wgk
1
ridadr
UN1230 - class 3 - PG 2 - Methanol, solution
hs_code
2939110015
risk_code
11-23/24/25-39/23/24/25-26/27/28
hazard_code
F,T,T+
safety_code
16-36/37-45-36/37/39-22
Speicherklasse
3 - Flammable liquids
Giftige Stoffe Daten
76-41-5(Hazardous Substances Data)
Hazard Classifications
Acute Tox. 3 DermalAcute Tox. 3 InhalationAcute Tox. 3 OralFlam. Liq. 2STOT SE 1

Opioids produce respiratory depression, likely by a direct action on brain stem respiratory centers. The respiratory depression involves a reduction in the responsiveness of the brain stem respiratory centers to both increases in carbon dioxide tension and electrical stimulation.

Opioids depress the cough reflex by direct effect on the cough center in the medulla oblongata. Antitussive effects may occur with doses lower than those usually required for analgesia. Opioids cause miosis, even in total darkness. Pinpoint pupils are a sign of opioid overdose but are not pathognomonic (e.g., pontine lesions of hemorrhagic or ischemic origin may produce similar findings). Marked mydriasis rather than miosis may be seen with hypoxia in overdose situations

For more Mechanism of Action (Complete) data for Oxymorphone (9 total), please visit the HSDB record page.

Biological Half-Life1.3 (+/-0.7) hours
Metabolism/Metabolites · 3 Einträge

Oxymorphone undergoes extensive hepatic metabolism in humans. After a 10 mg oral dose, 49% was excreted over a five-day period in the urine. Of this, 82% was excreted in the first 24 hours after administration. The recovered drug-related products contained the oxymorphone (1.9%), the conjugate of oxymorphone (44.1%), the 6(beta)-carbinol produced by 6-keto reduction of oxymorphone (0.3%), and the conjugates of 6(beta)-carbinol (2.6%) and 6(alpha)-carbinol (0.1%).

Oxymorphone is highly metabolized, principally in the liver, and undergoes reduction or conjugation with glucuronic acid to form both active and inactive products. The two major metabolites of oxymorphone are oxymorphone-3-glucuronide and 6-OH-oxymorphone.

Oxymorphone undergoes extensive hepatic metabolism in humans. After a 10 mg oral dose, 49% was excreted over a five-day period in the urine. Of this, 82% was excreted in the first 24 hours after administration. The recovered drug-related products contained the oxymorphone (1.9%), the conjugate of oxymorphone (44.1%), the 6(beta)-carbinol produced by 6-keto reduction of oxymorphone (0.3%), and the conjugates of 6(beta)-carbinol (2.6%) and 6(alpha)-carbinol (0.1%). Route of Elimination: Oxymorphone is highly metabolized, principally in the liver, and undergoes reduction or conjugation with glucuronic acid to form both active and inactive products. Because oxymorphone is extensively metabolized, <1% of the administered dose is excreted unchanged in the urine. Half Life: 1.3 (+/-0.7) hours

FDA Pharmacological Classification · 5 Einträge

9VXA968E0C

OXYMORPHONE

Mechanisms of Action [MoA] - Full Opioid Agonists

Established Pharmacologic Class [EPC] - Opioid Agonist

Oxymorphone is an Opioid Agonist. The mechanism of action of oxymorphone is as a Full Opioid Agonist.

MeSH Pharmacological Classification · 3 Einträge

Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS.

Agents that are administered in association with anesthetics to increase effectiveness, improve delivery, or decrease required dosage.

Agents that induce NARCOSIS. Narcotics include agents that cause somnolence or induced sleep (STUPOR); natural or synthetic derivatives of OPIUM or MORPHINE or any substance that has such effects. They are potent inducers of ANALGESIA and OPIOID-RELATED DISORDERS.

Absorption, Distribution and Excretion · 6 Einträge

Oxymorphone is highly metabolized, principally in the liver, and undergoes reduction or conjugation with glucuronic acid to form both active and inactive products. Because oxymorphone is extensively metabolized, <1% of the administered dose is excreted unchanged in the urine.

Oxymorphone is well absorbed following subcutaneous, im, or iv administration. Onset of action usually occurs within 5-10 minutes after iv administration and 10-15 minutes after subcutaneous or im administration. Analgesia is maintained for 3-6 hours following parenteral administration.

Following oral administration of oxymorphone hydrochloride, bioavailability is approximately 10%. Following oral administration of oxymorphone hydrochloride conventional tablets with a high-fat meal, peak plasma concentrations and area under the concentration-time curve (AUC) were increased 38%.

Following oral administration of oxymorphone hydrochloride extended-release tablets with food, peak plasma concentrations were increased 50%; AUC reportedly was unchanged in one study and increased 18% in another study. Bioavailability of oxymorphone was increased in patients with renal impairment, those with hepatic impairment, and in geriatric individuals following administration as extended-release tablets.

After an iv dose, the steady state volume of distribution was 3.08 +/- 1.14 L/kg in healthy male and female subjects.

For more Absorption, Distribution and Excretion (Complete) data for Oxymorphone (12 total), please visit the HSDB record page.

Cellular LocationsMembrane
Metabolite PathwaysOxymorphone Action Pathway

Verwendung und Herstellung

Uses · 5 Einträge

Oxymorphone is a Schedule II controlled substance.

Schedule II Controlled Substance: (A) The drug or other substance has a high potential for abuse; (B) The drug or other substance has a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions; and (C) Abuse of the drug or other substances may lead to severe psychological or physical dependence.

MEDICATION

MEDICATION (VET)

For the treatment of moderate-to-severe pain.

Methods of Manufacturing · 2 Einträge

Oxycodone is hydrolyzed with boiling concentrated hydrobromic acid.

Thebaine is dissolved in aqueous formic acid and treated with 30% hydrogen peroxide, after which neutralization with aqueous ammonia yields 14-hydroxycodeinone. This then is dissolved in acetic acid and hydrogenated with the aid of palladium-charcoal catalyst to form 14-hydroxy-7,8-dihydrocodeinone (oxycodone). In the form of its hydrochloride, this compound is demethylated by means of heating with pyridine hydrochloride to yield crude oxymorphone hydrochloride, which is then purified. /Oxymorphone hydrochloride/

Formulations/Preparations · 2 Einträge

Street Names: Blue Heaven, Blues, Mrs. O, New Blues, Octagons, Oranges, Orgasna IR, OM, Pink, Pink Heaven, Pink Lady, Pink O, Stop Signs, and The O Bomb.

Table: Oxymorphone Hydrochloride Preparations [Table#8046]

Use ClassificationPharmaceuticals
General Manufacturing InformationOxymorphone injection is an opioid agonist and a Schedule II controlled substance with an abuse liability similar to morphine.

Anwendungen

VerwendenControlled substance (opiate). Analgesic (narcotic)

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

WasserstoffHydrogenbromidTHEBAINEWasserstoffperoxid(5α)-4,5-Epoxy-3,14-dihydroxymorphinan-6-on

Nachgelagerte Produkte

HydromorphinolNalbuphinNaloxon

For more Human Toxicity Excerpts (Complete) data for Oxymorphone (7 total), please visit the HSDB record page.